drugset / Trial / NCT04739111
An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor
Phase 1
Completed
12 enrolled
Dragonboat Biopharmaceutical Company Limited
West China Hospital · collab
NaSequentialOpen-labelTreatment
Summary
This is an exploratory clinical study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in patients with advanced malignant tumor.
Timeline
- Start
- 2021-01-29
- Primary completion
- 2022-09-05
- Completion
- 2022-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDP1 | Monoclonal antibody | 250 mg/m2 | — |
| Subject | LDP | Monoclonal antibody | 5 mg/kg | — |
| Subject | LDP | Monoclonal antibody | 10 mg/kg | — |
| Subject | LDP | Monoclonal antibody | 20 mg/kg | — |